BMRA Biomerica Inc.

Biomerica to Participate in 14th Annual Craig-Hallum Alpha Select Conference on November 16

Biomerica to Participate in 14th Annual Craig-Hallum Alpha Select Conference on November 16

IRVINE, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products today announced that it will participate in the 14th Annual Craig-Hallum Alpha Select Conference on November 16, 2023, at the Sheraton New York Times Square Hotel in New York City. Zackary Irani, Chief Executive Officer of Biomerica will be hosting meetings during the event, which consists of one-on-one and small group meetings.

About Biomerica (NASDAQ: )

Biomerica, Inc. (www..com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica is primarily focused on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.

Corporate Contact:

Zack Irani

949-645-2111

Source: Biomerica, Inc.



EN
10/11/2023

Underlying

BMRABiomerica Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biomerica Inc.

 PRESS RELEASE
Free
BMRA BIOMERICA INC.

Biomerica Secures Three Key International Patents for inFoods® Technol...

Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn’s Disease, and Ulcerative Colitis New patents position Biomerica to address multi-billion-dollar markets in Europe, including GERD ($4 billion+), Crohn’s Disease ($2.5 billion+), and Ulcerative Colitis ($1.9 billion+) The company received three notices of allowance in countries within the European Patent Organization (EPO), including Germany, UK, France, Italy, Spain, and over 30 additional nations within the European Patent Treaty IRVINE, Calif., Nov. 21, 2024 (GLOBE NEWSWIR...

November 21, 2024 1 EN
 PRESS RELEASE
Free
BMRA BIOMERICA INC.

Nasdaq grants Biomerica an additional 180 days to meet listing complia...

Nasdaq grants Biomerica an additional 180 days to meet listing compliance requirements IRVINE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a leading global provider of advanced medical diagnostics, announced that it has been granted an additional 180-day compliance period from the Nasdaq Stock Market LLC ("Nasdaq") to meet the minimum $1.00 per share bid price requirement for continued listing on the Nasdaq Capital Market. This extension allows Biomerica until May 5, 2025, to regain compliance. This extension was provided because Biomerica currently meets th...

November 7, 2024 1 EN
 PRESS RELEASE
Free
BMRA BIOMERICA INC.

Biomerica Announces Direct-to-Consumer Availability of inFoods® IBS Te...

Biomerica Announces Direct-to-Consumer Availability of inFoods® IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain Patients experiencing bloating and gastrointestinal discomfort can now order inFoods® IBS directly from without needing to visit a doctor’s officeWith a simple, at-home finger-prick blood sample, patients can receive a personalized test result identifying potential IBS trigger foods The inFoods® IBS test empowers patients with actionable results to reduce bloating and gastrointestinal pain IRVINE, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. ...

October 30, 2024 1 EN
 PRESS RELEASE
Free
BMRA BIOMERICA INC.

Biomerica Reports First Quarter Fiscal 2025 Financial Results

Biomerica Reports First Quarter Fiscal 2025 Financial Results Total Revenue Increases 6% Over Same Period Last Year Cost-Saving Measures Now Implemented, Expected to Reduce Annual Expenses by 16% to 23%, Representing $1.0 to $1.4 Million ReductionBiomerica's At-Home PSA Screening Test Receives Saudi Food and Drug Authority (SFDA) Approval for Early Detection of Prostate Cancer IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reporte...

October 16, 2024 1 EN
 PRESS RELEASE
Free
BMRA BIOMERICA INC.

The Saudi Food and Drug Authority (SFDA) Approves Biomerica's At Home ...

The Saudi Food and Drug Authority (SFDA) Approves Biomerica's At Home PSA Screening Test to Detect Early Signs of Prostate Cancer - 10-Minute At-Home PSA Test for Early Detection of Prostate Cancer - First order already shipped to Saudi Arabia - Prostate Cancer is the Second Most Common Cancer in Men Globally IRVINE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) is pleased to announce that the Saudi Food and Drug Authority (SFDA) has approved the Company's Fortel® Prostate (PSA) Screening Test to be sold and used in the country. This at-home test...

September 4, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch